DBV Technologies Screens First Infant for THRIVE Phase 2 Peanut Allergy Trial

DBV Technologies has screened the first participant for its THRIVE Phase 2 clinical trial, which evaluates the safety and efficacy of the Viaskin Peanut patch in infants aged 6 to 12 months diagnosed with a peanut allergy. This study marks the company’s latest effort to assess the potential of its epicutaneous immunotherapy technology in a younger patient population.

The THRIVE study aims to gather data on how the patch performs in infants who are in the early stages of development. Researchers will monitor participants to determine the safety profile of the treatment and its impact on peanut allergy management within this specific age group. The company initiated this screening process as part of its broader clinical development program for the Viaskin platform, which utilizes a patch to deliver small amounts of allergen to the immune system through the skin.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI